英格兰国民保健制度信托机构为BRCA突变的妇女提供一种新的非外科卵巢癌测试,利用血标记和遗传学来早期检测癌症。 An NHS trust in England offers a new non-surgical ovarian cancer test for women with BRCA mutations, using blood markers and genetics to detect cancer earlier.

英格兰国家卫生服务署的一家信托基金为有BRCA1或BRCA2基因突变的妇女启动了一项新的卵巢癌监测测试,为预防外科手术提供了非外科的替代方法。 An NHS trust in England has launched a new ovarian cancer surveillance test for women with BRCA1 or BRCA2 gene mutations, offering a non-surgical alternative to preventive surgery. Ovarian癌症算术(Roca)的风险跟踪CA125水平随时间推移的变化,同时跟踪年龄、更年期状况和遗传学,以发现即使在正常范围内也呈上升趋势,从而能够及早发现癌症。 The Risk of Ovarian Cancer Algorithm (Roca) tracks changes in CA 125 levels over time, along with age, menopausal status, and genetics, to detect rising trends even within normal ranges, enabling earlier cancer detection. 研究表明,它可以将晚期诊断减半。 Studies suggest it can halve late-stage diagnoses. 该方案由大学学院伦敦医院和国民保健服务基金会信托基金与合作伙伴牵头,旨在在全国推广,利用中央实验室测试,以确保一致性和减少护理方面的差距。 Led by University College London Hospitals NHS Foundation Trust with partners, the program aims to expand nationally, using centralized lab testing to ensure consistency and reduce disparities in care.